<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760617</url>
  </required_header>
  <id_info>
    <org_study_id>111737</org_study_id>
    <nct_id>NCT00760617</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older</brief_title>
  <official_title>Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline
      Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.

      This protocol posting deals with objectives &amp; outcome measures of the extension phase at year
      1. The objectives &amp; outcome measures of the primary phase are presented in a separate
      protocol posting (NCT number = 00540592).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Grade 3 ecchymosis, redness and swelling was greater than or equal to 100 millimeter (mm) i.e. ≥ 100 mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Duration was defined as number of days with any grade of local symptoms and grade for quantifiable symptoms: ecchymosis, redness and swelling was greater than (&gt;) 20mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature &gt;40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to vaccination, grade 3 was defined as a general symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>Day 0-20</time_frame>
    <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as possibly related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 0 to 20</measure>
    <time_frame>Day 0-20</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 21 to 179</measure>
    <time_frame>Day 21-179</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Disease (AID)</measure>
    <time_frame>Day 0-179</time_frame>
    <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoiimune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 to Day 20</measure>
    <time_frame>Day 0-20</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 to Day 179</measure>
    <time_frame>Day 21-179</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 180 to Day 209</measure>
    <time_frame>Day 180 to Day 209</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Antibody titers were expressed as Geometric mean titres (GMTs) with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Antibody titers were expressed as GMTs with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies at Day 0 and 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre &lt;1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factor (SCF) at Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody SCF at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and Day 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</measure>
    <time_frame>At Day 0 and 21</time_frame>
    <description>The markers assessed were CD4-ALL DOUBLES, CD40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix young Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK2186877A</intervention_name>
    <description>Intramuscular (IM) administration, 1 dose</description>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>Intramuscular (IM) administration, 1 dose</description>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_label>Fluarix young Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A male or female aged 18-41 years or ≥65 years at the time of the vaccination and who
             participated in the 110847 study and completed the 6 month follow-up.

          -  Written informed consent obtained from the subject.

          -  Fee of acute aggravation of the health status as established by clinical evaluation
             (medical history and medical history directed examination) before entering into the
             study.

          -  Female subjects must be of non-childbearing potential.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days prior to vaccination, or planned use during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of an influenza vaccine other than the study vaccines or of a vaccine not foreseen in
             the study protocol during the entire study period.

          -  Vaccination against influenza since January 2008 with a seasonal influenza vaccine.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the administration of the study
             vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of hypersensivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s).

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by clinical evaluation (medical history and
             medical history directed physical examination) or pre-existing laboratory screening
             tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first administration of the study vaccine or planned administration
             during the study.

          -  Any medical conditions in which IM injections are contraindicated.

          -  Lactating female, female planning to become pregnant or planning to discontinue
             contraceptive precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rudersberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolmirstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3001 DC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2012</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111737</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="P3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="B3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="116"/>
            <count group_id="B4" value="526"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="5.27"/>
                    <measurement group_id="B2" value="73.8" spread="5.54"/>
                    <measurement group_id="B3" value="28.2" spread="6.34"/>
                    <measurement group_id="B4" value="63.59" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, redness and swelling was greater than or equal to 100 millimeter (mm) i.e. ≥ 100 mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 ecchymosis, redness and swelling was greater than or equal to 100 millimeter (mm) i.e. ≥ 100 mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as number of days with any grade of local symptoms and grade for quantifiable symptoms: ecchymosis, redness and swelling was greater than (&gt;) 20mm.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs</title>
          <description>Duration was defined as number of days with any grade of local symptoms and grade for quantifiable symptoms: ecchymosis, redness and swelling was greater than (&gt;) 20mm.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N= 2; 2; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="6.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=108; 18; 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=43; 5; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=20; 7; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature &gt;40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to vaccination, grade 3 was defined as a general symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature &gt;40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to vaccination, grade 3 was defined as a general symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General AEs</title>
          <description>Duration was defined as number of days with any grade of general symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=30; 6; 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=51; 11; 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms (N=24; 5; 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=39; 7; 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=42; 8; 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=37; 6; 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=5; 1; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as possibly related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
          <description>Unsolicited adverse event (AE) covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as possibly related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 0 to 20</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 0 to 20</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 21 to 179</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
        <time_frame>Day 21-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit Between Day 21 to 179</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Disease (AID)</title>
        <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoiimune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
        <time_frame>Day 0-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Disease (AID)</title>
          <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoiimune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as possibly related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 to Day 20</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 0 to Day 20</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 to Day 179</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 21-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) Between Day 21 to Day 179</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 180 to Day 209</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 180 to Day 209</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 180 to Day 209</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</title>
        <description>Antibody titers were expressed as Geometric mean titres (GMTs) with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</title>
          <description>Antibody titers were expressed as Geometric mean titres (GMTs) with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="24.7" upper_limit="31.6"/>
                    <measurement group_id="O2" value="22.9" lower_limit="19.6" upper_limit="26.7"/>
                    <measurement group_id="O3" value="43.2" lower_limit="33.9" upper_limit="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="66.7" upper_limit="83.3"/>
                    <measurement group_id="O2" value="57.5" lower_limit="49.5" upper_limit="66.8"/>
                    <measurement group_id="O3" value="164.7" lower_limit="133.9" upper_limit="202.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="24.3" upper_limit="32.6"/>
                    <measurement group_id="O2" value="22.8" lower_limit="19.0" upper_limit="27.4"/>
                    <measurement group_id="O3" value="28.9" lower_limit="22.9" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.9" lower_limit="213.5" upper_limit="278.7"/>
                    <measurement group_id="O2" value="134.8" lower_limit="107.9" upper_limit="168.4"/>
                    <measurement group_id="O3" value="171.1" lower_limit="141.0" upper_limit="207.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.5" lower_limit="111.5" upper_limit="143.5"/>
                    <measurement group_id="O2" value="159.9" lower_limit="136.1" upper_limit="188.0"/>
                    <measurement group_id="O3" value="192.7" lower_limit="150.6" upper_limit="246.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519.0" lower_limit="467.1" upper_limit="576.6"/>
                    <measurement group_id="O2" value="402.5" lower_limit="344.2" upper_limit="470.6"/>
                    <measurement group_id="O3" value="711.5" lower_limit="611.2" upper_limit="828.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers at Day 180</title>
        <description>Antibody titers were expressed as GMTs with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers at Day 180</title>
          <description>Antibody titers were expressed as GMTs with separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="30.9" upper_limit="39.4"/>
                    <measurement group_id="O2" value="27.7" lower_limit="23.9" upper_limit="32.0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="79.8" upper_limit="124.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="77.0" upper_limit="105.4"/>
                    <measurement group_id="O2" value="69.9" lower_limit="55.8" upper_limit="87.6"/>
                    <measurement group_id="O3" value="86.1" lower_limit="68.2" upper_limit="108.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain (N=241; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.7" lower_limit="248.4" upper_limit="312.6"/>
                    <measurement group_id="O2" value="255.7" lower_limit="218.9" upper_limit="298.7"/>
                    <measurement group_id="O3" value="463.3" lower_limit="384.0" upper_limit="558.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies at Day 0 and 21</title>
        <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seropositive to HI Antibodies at Day 0 and 21</title>
          <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies at Day 180</title>
        <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seropositive to HI Antibodies at Day 180</title>
          <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain (N=241; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
        <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
          <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
        <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre &lt;1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
          <description>Seroconversion was defined as the percentage of vaccinees who had either a pre-vaccination titre &lt;1:10 and a post-vaccination titre ≥1:40 or a pre-vaccination titre ≥1:10 and at least a 4-fold increase in post-vaccination titre. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain (N=241; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factor (SCF) at Day 21</title>
        <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factor (SCF) at Day 21</title>
          <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.4" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.1" upper_limit="2.9"/>
                    <measurement group_id="O3" value="3.8" lower_limit="3.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.5" upper_limit="9.9"/>
                    <measurement group_id="O2" value="5.9" lower_limit="4.9" upper_limit="7.2"/>
                    <measurement group_id="O3" value="5.9" lower_limit="4.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.6" upper_limit="4.6"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.2" upper_limit="2.9"/>
                    <measurement group_id="O3" value="3.7" lower_limit="3.0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody SCF at Day 180</title>
        <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody SCF at Day 180</title>
          <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O3" value="2.4" lower_limit="1.9" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.0" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.4" upper_limit="3.6"/>
                    <measurement group_id="O3" value="3.1" lower_limit="2.5" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain (N=241; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="2.0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O3" value="2.7" lower_limit="2.3" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and Day 21</title>
        <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Day 0 and Day 21</title>
          <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for HI which included all evaluable subjects for whom data concerning immunogenicity HI outcome measures were available at day 21.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="123"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
        <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
          <description>Seroprotection was defined as the percentage of vaccinees with a serum HI titre ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available at day 180.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain (N=240; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain (N=241; 130; 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</title>
        <description>The markers assessed were CD4-ALL DOUBLES, CD40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 0 and 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</title>
          <description>The markers assessed were CD4-ALL DOUBLES, CD40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort for cell mediated immunity (CMI) which included subjects for whom data concerning immunogenicity CMI outcome measures were available at day 21.</population>
          <units>cells per million CD4 T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [CD4-ALL DOUBLES] Day 0 (N=66; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.28" spread="492.55"/>
                    <measurement group_id="O2" value="682.47" spread="759.31"/>
                    <measurement group_id="O3" value="1179.17" spread="1031.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-ALL DOUBLES] Day 21 (N=66; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1431.41" spread="679.60"/>
                    <measurement group_id="O2" value="972.14" spread="1204.18"/>
                    <measurement group_id="O3" value="1513.30" spread="798.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-ALL DOUBLES] Day 0 (N=65; 33; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.86" spread="419.39"/>
                    <measurement group_id="O2" value="444.42" spread="578.82"/>
                    <measurement group_id="O3" value="743.45" spread="552.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-ALL DOUBLES] Day 21 (N=66; 32; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912.85" spread="496.53"/>
                    <measurement group_id="O2" value="592.66" spread="518.19"/>
                    <measurement group_id="O3" value="912.28" spread="476.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-ALL DOUBLES] Day 0 (N=65; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="828.74" spread="840.19"/>
                    <measurement group_id="O2" value="679.28" spread="702.37"/>
                    <measurement group_id="O3" value="1045.61" spread="510.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-ALL DOUBLES] Day 21 (N=64; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1361.30" spread="799.10"/>
                    <measurement group_id="O2" value="935.28" spread="1130.22"/>
                    <measurement group_id="O3" value="1403.64" spread="580.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-CD40L] Day 0 (N=66; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="694.63" spread="452.67"/>
                    <measurement group_id="O2" value="616.27" spread="682.26"/>
                    <measurement group_id="O3" value="1127.82" spread="946.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-CD40L] Day 21 (N=66; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1305.74" spread="622.93"/>
                    <measurement group_id="O2" value="855.81" spread="974.19"/>
                    <measurement group_id="O3" value="1379.47" spread="735.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-CD40L] Day 0 (N=65; 33; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.35" spread="368.33"/>
                    <measurement group_id="O2" value="361.18" spread="498.91"/>
                    <measurement group_id="O3" value="646.92" spread="542.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-CD40L] Day 21 (N=66; 32; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="803.34" spread="459.33"/>
                    <measurement group_id="O2" value="543.41" spread="463.96"/>
                    <measurement group_id="O3" value="816.08" spread="447.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-CD40L] Day 0 (N=65; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="775.18" spread="754.90"/>
                    <measurement group_id="O2" value="630.27" spread="630.81"/>
                    <measurement group_id="O3" value="959.42" spread="465.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-CD40L] Day 21 (N=64; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230.63" spread="731.08"/>
                    <measurement group_id="O2" value="850.96" spread="901.02"/>
                    <measurement group_id="O3" value="1275.70" spread="508.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IFN-γ] Day 0 (N=66; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.40" spread="373.24"/>
                    <measurement group_id="O2" value="338.29" spread="613.41"/>
                    <measurement group_id="O3" value="777.72" spread="837.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IFN-γ] Day 21 (N=66; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.94" spread="536.38"/>
                    <measurement group_id="O2" value="481.04" spread="976.79"/>
                    <measurement group_id="O3" value="985.11" spread="713.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IFN-γ] Day 0 (N=65; 33; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.79" spread="321.42"/>
                    <measurement group_id="O2" value="301.64" spread="426.04"/>
                    <measurement group_id="O3" value="501.13" spread="482.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IFN-γ] Day 21 (N=66; 32; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628.36" spread="400.49"/>
                    <measurement group_id="O2" value="399.84" spread="387.97"/>
                    <measurement group_id="O3" value="638.93" spread="418.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IFN-γ] Day 0 (N=65; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.23" spread="708.32"/>
                    <measurement group_id="O2" value="299.25" spread="441.05"/>
                    <measurement group_id="O3" value="681.49" spread="413.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IFN-γ] Day 21 (N=64; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800.89" spread="648.91"/>
                    <measurement group_id="O2" value="478.15" spread="851.02"/>
                    <measurement group_id="O3" value="934.53" spread="471.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IL2] Day 0 (N=66; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645.57" spread="445.17"/>
                    <measurement group_id="O2" value="542.90" spread="700.45"/>
                    <measurement group_id="O3" value="1033.28" spread="884.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IL2] Day 21 (N=66; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1176.29" spread="568.05"/>
                    <measurement group_id="O2" value="816.63" spread="1114.87"/>
                    <measurement group_id="O3" value="1259.69" spread="691.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IL2] Day 0 (N=65; 33; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.93" spread="375.33"/>
                    <measurement group_id="O2" value="392.63" spread="488.21"/>
                    <measurement group_id="O3" value="599.02" spread="523.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IL2] Day 21 (N=66; 32; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745.33" spread="428.75"/>
                    <measurement group_id="O2" value="505.78" spread="459.04"/>
                    <measurement group_id="O3" value="745.61" spread="444.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IL2] Day 0 (N=65; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="711.32" spread="760.06"/>
                    <measurement group_id="O2" value="547.71" spread="646.50"/>
                    <measurement group_id="O3" value="852.51" spread="479.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IL2] Day 21 (N=64; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1112.52" spread="725.72"/>
                    <measurement group_id="O2" value="778.12" spread="1034.69"/>
                    <measurement group_id="O3" value="1156.73" spread="494.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-TNF-α] Day 0 (N=66; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.82" spread="442.61"/>
                    <measurement group_id="O2" value="610.09" spread="669.96"/>
                    <measurement group_id="O3" value="900.67" spread="914.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-TNF-α] Day 21 (N=66; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1057.44" spread="568.35"/>
                    <measurement group_id="O2" value="749.70" spread="1068.11"/>
                    <measurement group_id="O3" value="1096.74" spread="689.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-TNF-α] Day 0 (N=65; 33; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.12" spread="403.06"/>
                    <measurement group_id="O2" value="414.27" spread="508.57"/>
                    <measurement group_id="O3" value="575.28" spread="509.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-TNF-α] Day 21 (N=66; 32; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="740.68" spread="448.67"/>
                    <measurement group_id="O2" value="449.51" spread="463.77"/>
                    <measurement group_id="O3" value="685.63" spread="429.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-TNF-α] Day 0 (N=65; 34; 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646.27" spread="718.92"/>
                    <measurement group_id="O2" value="558.87" spread="591.29"/>
                    <measurement group_id="O3" value="818.77" spread="441.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-TNF-α] Day 21 (N=64; 34; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021.43" spread="690.24"/>
                    <measurement group_id="O2" value="715.45" spread="973.99"/>
                    <measurement group_id="O3" value="1023.28" spread="475.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed during Day 0-20, Day 21-179 and Day 180-209. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 and 21 day post vaccination period respectively.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥65 years received 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="E3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 18-40 years received 1 dose of Fluarix vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Locked-in syndrome</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <description>SAE assessed from Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <description>SAE assessed from Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <description>SAE assessed from Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <description>SAE assessed from Day 0 to Day 20.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>SAE assessed from Day 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <description>SAE assessed between Day 21 and Day 179.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

